Article

Targeting CD33 for Acute Myeloid Leukemia Therapy

2021-09-09

Abstract excerpt

<title>Abstract</title> <p>Objective The aim of this study was to analyze the level of CD33 expression in patients with newly diagnosed AML and determine its correlation with clinical characteristics. <h4>Methods:</h4> Samples were collected for analysis from AML patients at diagnosis. We evaluated the level of CD33 expression by flow cytometry analysis of bone marrow. Chi-square or t- tests were used to assess...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8f2dc868-6105-5e58-85b7-eecea445c65e
DOI: 10.21203/rs.3.rs-847355/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting CD33 for Acute Myeloid Leukemia TherapyDOI 10.21203/rs.3.rs-847355/v1Read

Targeting CD33 for acute myeloid leukemia therapy.Semantic proximity Read

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaSemantic proximity Read

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Semantic proximity Read

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemiaSemantic proximity Read

Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.Semantic proximity Read

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia TreatmentSemantic proximity Read

Differences in CD33 Intensity Between Various Myeloid NeoplasmsSemantic proximity Read

High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation.Semantic proximity Read

Gemtuzumab ozogamicin in acute myeloid leukemia.Semantic proximity Read

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agentsSemantic proximity Read

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Semantic proximity Read

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.Semantic proximity Read